Processa Pharmaceuticals (PCSA) Interview: Phase 2 Breast Cancer Data, Pipeline Strategy & FDA Path

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/bf/b0/a0/bfb0a050-9d15-b843-3b2a-ab8a774382fc/mza_17908578731465340111.jpg/600x600bb.jpg

Small Stocks, Big Money

RedChip Companies

121 episodes

1 week ago

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. Founded in 1992, and headquartered in Orlando, Florida, with affiliates in New York and Pittsburgh, RedChip has helped hundreds of companies achieve their capital markets goals. RedChip has been ranked by Inc. magazine as one of the fastest growing privately held investor relations firms in the U.S. RedChip represents 70+ emerging growth companies in a variety of industries including Biotechnology and BioPharma, Business Services, Consumer Goods, High Tech, Mining and Minerals.

Business

RSS

All content for Small Stocks, Big Money is the property of RedChip Companies and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Business

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38420737/38420737-1689948917073-c156b20bb02fe.jpg

Processa Pharmaceuticals (PCSA) Interview: Phase 2 Breast Cancer Data, Pipeline Strategy & FDA Path

Small Stocks, Big Money

7 minutes 10 seconds

3 weeks ago

Processa Pharmaceuticals (PCSA) Interview: Phase 2 Breast Cancer Data, Pipeline Strategy & FDA Path

In this exclusive interview, David Young, PhD, President of Research & Development and Founder of Processa Pharmaceuticals (Nasdaq: PCSA), breaks down the latest Phase 2 clinical progress for the company’s lead oncology program targeting advanced breast cancer.🔬 Key Topics We Covered:• Positive preliminary Phase 2 data from the oral combination therapy PCS6422 + capecitabine• Evidence showing ~10x increase in cancer-killing metabolites while maintaining similar side effect severity versus standard capecitabine• How Processa’s approach aims to improve efficacy without increasing toxicity• Details on the formal 20-patient interim analysis evaluating safety and efficacy, expected in 2026• How this program could potentially replace current capecitabine monotherapy in certain breast cancer settings• Insights into the FDA development pathway and dose optimization ahead of a potential pivotal trial🎯 David Young brings over 40 years of experience in chemotherapy drug development, including deep expertise in 5-FU and capecitabine metabolism, which uniquely positions him to lead Processa’s clinical innovation.👉 Processa Pharmaceuticals is a client of RedChip. To learn more about PCSA and to read our full disclosure, visit: PCSAinfo.com.#ProcessaPharmaceuticals #PCSA #BiotechStocks #SmallCapStocks #Oncology #BreastCancerResearch #ClinicalTrials #Phase2Trial #CancerTherapeutics #BiotechInvesting #HealthcareStocks #NASDAQStocks #DrugDevelopment #FDAApproval #LifeSciences #GrowthStocks #InvestorInterview